Rolf Koehler

TL;DR: Standardized quantitative assessment of minimal residual disease based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD) at 2 time points (TPs) is introduced, to stratify patients in a large prospective study.

TL;DR: In this paper, the authors present a compilation of data for 144 distinct mutations that alter the coding sequence of the BMPR2 gene identified in 210 independent pulmonary arterial hypertension (PAH) subjects.

TL;DR: MRD ≥ 10(-3) at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL, and an excellent outcome was obtained in 32% of patients turning MRD negative only at TP1, indicating that early (TP1) MRD levels were irrelevant if MRD at TP 2 was negative.

TL;DR: In conclusion, MRD-PCR-based stratification using stringent criteria is feasible in almost 80% of patients in an international multicenter trial.

TL;DR: Common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 × 10−11), irrespective of cell lineage.